TrialBritish journal of clinical pharmacology2016

Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira(®) in healthy subjects.

Elizabeth Hyland et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.